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OBJECTIVE — To determine whether the peroxisome proliferator–activated receptor
(PPAR)- Pro12ala polymorphism modulates susceptibility to diabetes in South Asians.
RESEARCHDESIGNANDMETHODS— South Asians (n 697) and Caucasians (n
457) living in Dallas/Forth Worth, Texas, and South Asians living in Chennai, India (n 1,619),
were enrolled for this study. PPAR- Pro12Ala was determined using restriction fragment–
length polymorphism. Insulin responsiveness to an oral glucose tolerance test (OGTT) was
measured in nondiabetic subjects.
RESULTS— The Caucasian diabetic subjects had significantly lower prevalence of PPAR-
12Ala when compared with the Caucasian nondiabetic subjects (20 vs. 9%, P  0.006). How-
ever, there were no significant differences between diabetic and nondiabetic subjects with ref-
erence to the Pro12Ala polymorphism among the South Asians living in Dallas (20 vs. 23%) and
in India (19 vs. 19.3%). Although Caucasians carrying PPAR- Pro12Ala had lower plasma
insulin levels at 2 h of OGTT than the wild-type (Pro/Pro) carriers (76 68 and 54 33U/ml,
respectively, P 0.01), no differences in either fasting or 2-h plasma insulin concentrations were
found between South Asians carrying the PPAR- Pro12Ala polymorphism and those with the
wild-type genotype at either Chennai or Dallas.
CONCLUSIONS— Although further replication studies are necessary to test the validity of
the described genotype-phenotype relationship, our study supports the hypothesis that the
PPAR- Pro12Ala polymorphism is protective against diabetes in Caucasians but not in South
Asians.
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T ype 2 diabetes is highly prevalentin individuals of South-Asian ori-gin (from India, Pakistan, and Ban-
g l a d e s h ) w h e n c o m p a r e d w i t h
individuals of European descent (Cau-
casians) (1– 4). Genetic causes may ac-
count for predisposition to insulin
resistance and diabetes in South Asians
(4,5). Therefore, evaluation of genetic
defects that modulate the insulin signal-
ing pathway and determine predisposi-
tion to insulin resistance and type 2
diabetes in this population may shed
light on genetic causes of insulin resis-
tance and diabetes. Several candidate
genes for defects in insulin signaling
have been postulated, and a few studies
report positive associations between
polymorphisms of genes involved in the
insulin signaling pathway and insulin
resistance (6). We recently reported a
positive association between ENPP1-
K121Q polymorphism and type 2 dia-
betes both in Caucasians and in South
Asians studied at Dallas and at Chennai,
India (7). On the other hand, some ge-
netic polymorphisms have also been as-
sociated to improved insulin sensitivity
and protection from type 2 diabetes.
Among the latter is peroxisome prolif-
erator–activated receptor (PPAR)-
Pro12Ala (8 –12). The present study
was carried out to determine whether
this polymorphism contributes to mod-
ulate ethnic susceptibility to diabetes in
South Asians. To accomplish this goal,
we assessed the frequency of PPAR-
X12Ala in South Asians and in Cauca-
sians with and without diabetes. The
study was extended to include both
South Asians living in Dallas and South
Asians living in India. In addition, insu-
lin responsiveness to an oral glucose
load was measured in nondiabetic sub-
jects with PPAR- X12Ala versus the
wild type of these three study groups.
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RESEARCH DESIGN AND
METHODS— To determine whether
the frequency of the candidate genetic
polymorphisms was different in South
Asians and in Caucasians, we recruited
unrelated South Asians and Caucasians
living in Dallas by public advertisement
and offering free screening for cardiovas-
cular risk factors at the University of
Texas Southwestern Lipid and Heart Dis-
ease Risk Management Clinic in Dallas,
Texas. To determine the frequency of the
candidate genetic polymorphism in a
nonmigrant population living in India,
the study included a group of South
Asians enrolled in the Chennai Urban Ru-
ral Epidemiology Study (CURES) (13).
Institutional review board approval was
obtained for the study, and informed con-
sent was obtained from all study subjects.
Each of the participants was administered
a health questionnaire. A blood sample
was then drawn from each participant
and immediately refrigerated. After sepa-
ration of plasma and serum, aliquots were
frozen at80°C. Blood samples were col-
lected for biochemical and genetic stud-
ies. The presence of diabetes was
documented either by the use of hypogly-
cemic agents or by fasting plasma glucose
126 mg/dl and/or plasma glucose at
time 2 h of an oral glucose tolerance test
(OGTT)200 mg/dl. To further evaluate
the impact of the studied mutations on
insulin resistance, we invited the volun-
teers to participate in the second part of
the study, which included more detailed
anthropometric measurements (skin-
folds, waist and hip circumferences, and
underwater weighing in subjects studied
at Dallas) and an OGTT. Methods for
these procedures are reported elsewhere
(7). Subjects who were diagnosed to have
diabetes based on the World Health Or-
ganization criteria (fasting plasma glucose
126 mg/dl and/or 2-h plasma glucose
200 mg/dl) were added to the diabetic
group. All the subjects who had type 2
diabetes were defined by the absence of
ketosis and adequate insulin reserve as
demonstrated by response to oral hypo-
glycemic agents.
Biochemical parameters
Fasting plasma glucose (glucose oxidase–
peroxidase method), serum cholesterol
(cholesterol oxidase–peroxidase–
amidopyrine method), serum triglycer-
ides (glycerol phosphate oxidase–
peroxidase–amidopyrine method), and
HDL cholesterol (direct method–
polyethylene glycol–pretreated enzymes)
were measured using a Hitachi-912 Auto-
analyzer (Hitachi, Mannheim, Germany).
In all the samples from the Dallas cohort,
insulin was measured by radioimmunoas-
say at Linco Research (St. Louis, MO),
while at Chennai, it was measured using
the Dako enzyme-linked immunosorbent
assay kit (Dako Diagnostics). For quality
assurance, in a subsample of 120 subjects
from the Chennai cohort (30 nondiabetic
subjects with wild-type genotype, 30
nondiabetic subjects with Pro12Ala, 30
type 2 diabetic patients with wild-type ge-
notype, and 30 type 2 diabetic patients
with Pro12Ala), insulin was also mea-
sured using the same Linco insulin kit
used for the Dallas samples.
Bioelectric impedance measurements
at Chennai for the subjects were made us-
ing a Beurer body fat analyzer, which in-
corporates weighing scales and measures
both weight and bioimpedance (Beurer
BF 60; Beurer, Ulm, Germany). Imped-
ance measurements allow assessment of
the fat-free mass and, by difference with
body weight, assessment of body fat per-
centage.
Dual-energy X-ray absorptiometry
and computed tomography scan
Both these procedures were done for a
subset of South Asians from Chennai (n
164) on the same day by two different
observers at the Bharat Scans, Chennai, a
specialized center for imaging and radio-
logical studies. Both observers and the ra-
diologist who interpreted the scans were
unaware of the clinical status of the study
subjects. Subcutaneous and visceral fat
were measured using a Helical computed
tomography scan (General Electric, Mil-
waukee, WI). Dual-energy X-ray absorp-
tiometry was used to measure total body
fat, abdominal fat, nonabdominal fat, and
central abdominal fat. The machine used
was a Lunar Prodigy (Model 8743-BX/1L;
Lunar, Madison, WI).
DNA amplification by PCR
Fasting blood samples were drawn into
10-ml vacuum tubes containing EDTA.
Genomic DNA was isolated from whole
blood using commercial DNA isolation
kits from QIAGEN (Chatsworth, CA).
Assay of PPAR- Pro12Ala
polymorphisms
PCR amplification of the segment with the
Pro12Ala polymorphism was carried out
in a volume of 25 l, containing 100 ng
genomic DNA, 5 pmol of each primer,
and TaqDNA polymerase. The PCR con-
ditions were as follows: denaturation at
94°C for 3 min followed by 40 cycles of
denaturation for 30 s, annealing at 53°C
for 30 s, extension at 72°C, and final ex-
tension at 72°C for 9 min. The polymor-




CTTTCCG-3. The PCR product size is
273 bp. Restriction fragment–length
polymorphism was detected after diges-
tion overnight with 2 units of BstUI.
Statistical analysis and calculations
Homeostasis model assessment for insu-
lin resistance (HOMA-IR) was calculated
from fasting insulin and glucose concen-
trations (14). Matsuda insulin sensitivity
index was calculated from plasma glucose
and insulin concentrations during the
OGTT (15). Continuous demographic
variables were compared between South
Asians and Caucasians using the Mann-
Whitney U test. Frequencies of mutation
were compared between ethnic groups
using the Fisher’s exact test. Two-way
ANOVA models were used to assess ef-
fects of ethnicity, polymorphisms, and
the interaction between ethnic group and
polymorphisms. Multiple comparisons of
these group means were made with the
least-squares contrasts of the ANOVA
models. Because of skewness, triglycer-
ides and insulin were log transformed be-
fore analysis. Statistical analysis was
performed using SAS version 8.02 (SAS
Institute, Cary, NC).
RESULTS— A total of 1,619 South
Asians were recruited in Chennai within
the CURES epidemiological study (13);
697 subjects of South-Asian origin and
457 of European descent were recruited
in Dallas. The general characteristics of
diabetic and nondiabetic subjects are re-
ported in Table 1. The prevalence of hy-
pertension in type 2 diabetic subjects was
37% in South Asians living in Chennai,
45% in South Asians living in Dallas, and
15% in Caucasians living in Dallas. The
corresponding figures for nondiabetic
subjects were 8% (South Asians living in
Chennai), 15% (South Asians living in
Dallas), and 5% (Caucasians living in Dal-
las). Body fat measurements by computed
tomography and dual-energy X-ray ab-
sorptiometry revealed that diabetic sub-
jects had significantly higher visceral fat
(P  0.005) and central abdominal fat
(P  0.011) than nondiabetic subjects.
Visceral fat and central abdominal fat also
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showed a strong correlation with each
other (P 0.0001). Waist circumference
and sagittal abdominal diameter showed a
strong correlation with visceral fat (P 
0.01) and central abdominal fat (P 
0.0001) in both diabetic and nondiabetic
subjects.
There were 1% of South Asians (living
in either Dallas or Chennai) and 1% of
Caucasians with homozygosity of the
PPAR- 12Ala polymorphism. The allele
frequency of PPAR- 12 Ala was 10% in
the Caucasian group, 11% in the South-
Asian group from Dallas, and 10% in the
South-Asian group from Chennai. The ge-
notype frequencies were in Hardy-
Weinberg equilibrium in each subgroup.
Because of the small number of homozy-
gotes in the sample, individuals homozy-
gous (Ala/Ala) and heterozygous for
PPAR- 12Ala (Pro/Ala) were grouped to-
gether for analysis and identified as X/Ala.
As depicted in Fig. 1, the frequency of at
least one copy of PPAR- 12Ala was com-
parable among the nondiabetic subjects
of the three-study group (19% for the
South Asians living in Chennai, 21% for
the South Asians living in Dallas, and 21%
for the Caucasians living in Dallas).
Among the Caucasians, a significant de-
crease in frequency of PPAR- 12Ala was
found in the diabetic subgroup when
compared with the nondiabetic subjects
(20 vs. 9%, P  0.006). On the other
hand, no statistically significant differ-
ences in PPAR- Pro12Ala frequency
were found between diabetic and nondi-
abetic subjects among the South Asians
studied in Dallas or Chennai (20 vs. 23%
for the Dallas cohort; 19 vs. 19.3% for the
Chennai cohort).
A total of 976 South Asians (820 liv-
ing in Chennai and 156 living in Dallas)
and 151 Caucasians, who had no diabe-
tes, underwent OGTT. Within each study
group, there were no differences in gen-
eral characteristics, including BMI, body
fat content, and waist circumference be-
tween the carriers of the polymorphism
and the wild-type genotype (Table 2). Be-
cause the Chennai cohort was the largest,
we also compared general characteristics
and measures of insulin resistance in this
cohort separately for the heterozygous
(58 males and 89 females) and homozy-
gous (6 males and 5 females) subjects. No
differences were found for any of the vari-
ables analyzed (data not shown).
To assess any association between
PPAR- Ala carrier and improved insulin
sensitivity, we compared subgroups with
wild-type PPAR- and 12Ala carriers
within the same main study groups
(South Asians living in Chennai, South
Asians living in Dallas, and Caucasians
Figure 1—Frequency of PPAR- variants in Caucasians, South Asians living in Dallas, and South
Asians living in Chennai., nondiabetic participants; f, type 2 diabetic patients.






living in Dallas P
Nondiabetic subjects
n (M/F) 820 (299/521) 616 (363/253) 334 (168/166) 0.0001
Age (years) 41  13 42  13 37  14† 0.0001
BMI (kg/m2) 23.4  4.7 24.9  3.7* 25.4  5.4* 0.0001
Glucose (mg/dl) 85  8 96  23* 88  12† 0.0001
Total abdominal fat (cm2) 332.0  135.8 — — —
Visceral fat (cm2) 119.5  53.5 — — —
Subcutaneous abdominal fat (cm2) 208.7  118.6 — — —
Central abdominal fat (g) 1,368.4  510.1 — — —
Diabetic subjects
n (M/F) 799 (348/451) 81 (46/35) 123 (88/35) 0.0001
Age (years) 52  11 56  10* 59  8* 0.0001
BMI (kg/m2) 25.1  4.2 25.6  3.7 33.4  7.3† 0.0001
Glucose (mg/dl) 162  68 161  65 172  74 0.40
Total abdominal fat (cm2) 371.4  113.6 — — —
Visceral fat (cm2) 140.5  40.6 — — —
Subcutaneous abdominal fat (cm2) 230.1  97.5 — — —
Central abdominal fat (g) 1,547.7  371.7 — — —
Data are means SD unless otherwise indicated. P values were determined using ANOVA. SI conversion factors are as follows: 0.0555 mmol/l for glucose, 0.0259
mmol/l for cholesterol, and 0.0113 mmol/l for triglycerides. *P  0.05 vs. the South Asians living in Chennai; †P  0.05 vs. the South Asians living in Dallas.
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living in Dallas). Plasma insulin levels at
the 2-h OGTT increased by a similar de-
gree in the wild-type carrier and carrier of
the PPAR- 12Ala allele in both the
South-Asian populations (54  46 and
57  46 U/ml, respectively, for the
South Asians living in Chennai, and
104  90 and 101  55 U/ml, respec-
tively, for those living in Dallas) when
compared with baseline. However, the
2-h OGTT increase in plasma insulin con-
centrations was less in the Caucasians
who were carriers of the PPAR- 12Ala
polymorphism when compared with the
noncarriers (54 33 and 76 68U/ml
for the carriers and noncarriers, respec-
tively; P 0.01). No differences in fasting
plasma insulin and HOMA-IR were found
between carriers and wild-type carriers in
the three study cohorts. The plasma insu-
lin levels and the HOMA-IR values were
lower in the South Asians at Chennai
compared with the South Asians at Dallas.
To test whether this is due to differences
in assays, we compared plasma insulin
concentrations of a subset of 120 subjects
from the Chennai cohort using the Dako
and Linco kits (used at Dallas) on the
same samples. The Dako method used to
determine insulin in the whole Chennai
cohort underestimated plasma insulin
concentrations. The mean difference was
4.16 U/ml (95% CI 2.8–5.5) and 14.4
U/ml (11.2–17.7) for the baseline and
2-h insulin values, respectively.
CONCLUSIONS— There are two
major findings in this study. First, the fre-
quency of the PPAR- X12Ala polymor-
phism in South Asians is similar to that
seen in Caucasians. Second, whereas type
2 diabetes is associated with decreased
frequency of PPAR- X12Ala in people of
European descent, the prevalence of this
polymorphism is not decreased in type 2
diabetic subjects of South-Asian descent.
The PPAR- 12A polymorphism has
been reported to have a “protective” role
in diabetes risk (8–12). Although find-
ings have not been uniform (16–19), a
meta-analysis by Altshuler et al. (12) de-
termined that the presence of the 12Ala
allele confers20% reductions in risk for
diabetes. If PPAR- 12Ala had a protec-
tive effect on diabetes risk on various eth-
nic groups, one would expect lower 12Ala
allele frequency in populations character-
ized by a high prevalence of diabetes,
such as the South Asians. Contrary to this
expectation, we found a similar 12Ala al-
lele frequency in South Asians and in
Caucasians (10 and 11%, respectively).
A recent study on South Asians who mi-
grated to Singapore also reported a 12Ala
allele frequency of11% (19). Our study
was performed both in a migrant popula-
tion and in a homogeneous population of
South Asians residing in India. In both
populations, we observed a prevalence of
a 12Ala allele similar to that reported from
Singapore. The findings in the Caucasian
group living in Dallas are in concordance
with the published literature (8,9) and
confirm an allele frequency of 10% in
this ethnic group. In addition, our data
support the hypothesis of a protective role
of a 12Ala allele on diabetes risk in the
Caucasian population. As shown in Fig. 1,
the frequency of 12Ala was significantly
lower in the diabetic Caucasians when
compared with the nondiabetic Cauca-
sians. On the other hand, we show that
South-Asian diabetic and nondiabetic
subjects have virtually the same preva-
lence of 12Ala allele. Thus, our results
support the view that the PPAR- 12Ala
allele does not reduce the risk for diabetes
in South Asians. Similar findings were ob-
tained in South Asians, Chinese, and Ma-
lays living in Singapore (19).
Previous studies have linked the
12Ala allele with better insulin sensitivity
in Caucasians (7,8). However, these stud-
ies have often been confounded by the
presence of decreased BMI in the 12Ala
allele carriers, and no body composition
studies with direct measures of body fat
content and distribution were available.
In our study, we have two subgroups of
Caucasians with similar body composi-
tion and fat distribution. We also in-
cluded a biomarker of insulin resistance
with the measurement of plasma insulin
concentrations at 2 h from glucose in-
gestion during OGTT. This measure is
superior to fasting plasma insulin concen-
tration when estimating variability in in-
sulin area under the curve during OGTT
and better indicates insulin resistance
than fasting insulin concentrations (20).
We also compared another index of insu-
lin resistance, the Matsuda index (15),
across the study groups. Despite similar
glucose loads, the Caucasian group with
the 12Ala had a much lower increase in
plasma insulin concentrations at 2 h and a
trend toward a higher Matsuda index,
Table 2—Clinical profile of nondiabetic subjects who underwent an OGTT













n (M/F) 662 (235/427) 158 (64/94) 120 (80/40) 36 (23/13) 118 (47/71) 35 (15/18)
Age (years) 41  13 42  12 33  11 33  11 30  8 29  5
BMI (kg/m2) 23.4  4.5 23.5  5.1 23.8  3.7 24.3  3.4 24.9  5.9 25.4  4.1
Body fat (% body wt) 32.7  9.7 33.2  9.2 26.7  7.6 26.9  8.2 26.8  9.8 27.6  8.8
Waist (cm) 84  12 84  13 83  11 83  11 84  14 82  11
Systolic blood pressure (mmHg) 119  16 119  14 115  13 113  12 114  13 116  11
Diastolic blood pressure (mmHg) 75  10 74  9 72  11 69  11 70  12 69  8
Glucose (mg/dl) 85  6 85  8 91  12 97  11 92  9 90  6
Baseline insulin (U/ml) 9  6 9  6 16  22 18  25 12  9 11  6
HOMA-IR (index) 1.9  1.4 1.9  1.3 3.3  6.1 3.3  4.3 2.9  2.5 2.4  1.4
2-h OGTT insulin (U/ml) 54  46 57  46 104  90 101  55 76  68 54  33*
Insulin sensitivity index (Matsuda) 11.4  9.4 11.6  10.6 4.9  3.3 4.3  1.8 6.2  3.7 7.0  5.4
Data are means SD unless otherwise indicated. Each study group (South Asians living in Chennai, South Asians living in Dallas, and Caucasians living in Dallas)
was analyzed separately. P values were determined using the Student’s t test for independent groups. SI conversion factors are as follows: 0.0555 mmol/l for glucose,
0.0259 mmol/l for cholesterol, and 0.0113 mmol/l for triglycerides. *P  0.05 vs. the wild-type Caucasians living in Dallas.
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thus suggesting better biological activity
of insulin in disposal of glucose in periph-
eral cells. Of note, the association be-
tween allele 12Ala and better insulin
sensitivity was found despite similarities
in body composition and fat distribution.
In contrast to the findings of the Cauca-
sian group, the South Asians did not ex-
hibit any difference in 2-h plasma insulin
concentrations during the OGTT,
HOMA-IR, or Matsuda index. Because of
the differences in insulin concentration, it
appears that South Asians living in Dallas
are more insulin resistant that individuals
living in Chennai, despite minor differ-
ences in BMI. The reasons for the differ-
ences between South Asians living in
Chennai and those living in Dallas have
not been investigated in this study. Be-
sides the contribution of methodological
differences in measuring plasma insulin
in the two cohorts, a possible role of dif-
ferences in physical activity and diet can-
not be excluded (21). However, further
studies are required that are specifically
designed to address the issues of dietary
intake, physical activity, and insulin sen-
sitivity in these two populations. Regard-
less of the reasons for the differences in
insulin resistance between the two South-
Asian cohorts, the conclusions of our
study remain unchanged because the
comparisons were made between the Pro/
Pro and X/Ala groups at the respective
centers using the same insulin assay.
Taken together, these findings sug-
gest a lack of a “protective” role of 12Ala
allele on insulin resistance and risk for
type 2 diabetes in the South-Asian popu-
lation. Case-control studies, including
ours, are generally underpowered to al-
low firm conclusions on the association
between a given polymorphism and the
studied phenotype. Previous meta-
analyses have helped in estimating a sig-
nificant effect of PPAR- Pro12Ala on risk
reduction for type 2 diabetes in Cauca-
sians with an odds ratio of 0.80 (12).
However, not enough studies are avail-
able in multiple ethnic groups to deter-
mine whether ethnicity is a factor that
modulates the effects of this particular
polymorphism in predicting risk for dia-
betes. Although our study will need rep-
l i ca t ion in a la rger cohor t , the
concordance of results in the two South-
Asian groups of this study as well as the
study from Singapore in South Asians,
Chinese, and Malays (19) adds support to
the hypothesis that there are ethnic differ-
ences in the association between 12Ala
and type 2 diabetes. Our data suggest
the need for a more systematic evaluation
of gene-gene and environment-gene in-
teraction with the inclusion of a larger co-
hort of South Asians to explain ethnic
differences in phenotypic response to a
common polymorphism. The ethnic dif-
ferences in relation to the “protective” role
of allele 12Ala for diabetes risk may in fact
have both genetic and environmental or-
igins. The similarity of our findings be-
tween the South Asians living in Chennai
and those living in Dallas would support
gene-gene interaction as a major mecha-
nism for the observed ethnic differences.
It is possible that genetic interaction be-
tween PPAR- 12Ala with other polymor-
phisms involved in the regulation of
insulin signaling may determine de-
creased phenotypic expression of the
“protective” effect of the PPAR- 12Ala
allele. The role of gene-gene interaction
and also environment-gene interaction,
including diet and exercise, should be
systematically studied in the evaluation of
the ethnic heterogeneity reported here.
On this line, it is of interest that the aver-
age BMI was much lower in the South
Asians with diabetes than in the Cauca-
sians with diabetes. Contrary to the Cau-
casian population, little difference was
found between diabetic and nondiabetic
patients of South-Asian descent. This ob-
servation supports the view that excessive
insulin resistance and susceptibility to
type 2 diabetes in South Asians is likely
the result of a particular genetic milieu
that differs from that of Caucasians.
We conclude that despite the fre-
quency of the Ala allele at the PPAR-
Pro12Ala locus being high in individuals
of South-Asian descent, this particular
polymorphism does not appear to im-
prove insulin sensitivity and/or decrease
risk for type 2 diabetes in this ethnic
group, as it does in Caucasians. If con-
firmed by larger studies, the hypothesis
generated in this study may help us un-
derstand the susceptibility to insulin re-
sistance and excessive risk for type 2
diabetes observed in South Asians.
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